Search

Displaying results 3461 - 3470 of 5302 in total
  1. Drug

    Autogene cevumeran

    go.drugbank.com/drugs/DB17497
    Investigational

    Autogene cevumeran is an mRNA-based cancer vaccine targeting an unspecified amount of tumour-associated antigens. It is being investigated for cancers.

  2. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    [L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.

    Synonyms: N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
  3. Drug

    Molindone

    go.drugbank.com/drugs/DB01618
    Approved

    An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder.

  4. Drug

    Rocaglamide

    go.drugbank.com/drugs/DB15495
    Experimental

    Rocaglamide, also referred to as rocaglamide-A, is the eponymous member of a class of anti-cancer phytochemicals known as rocaglamides. Rocaglamides are secondary metabolites of the plant genus Aglaia, and extracts of the plant have trad...

  5. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved

  6. Drug

    Avutometinib

    go.drugbank.com/drugs/DB15254
    ApprovedInvestigational

    Avutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. The MAPK pathway is implicated in variety of cancers, playing a key role in tumor cell proliferation, diff...

  7. Drug

    Deoxycholic acid

    go.drugbank.com/drugs/DB03619
    ApprovedInvestigational

    Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholi...

  8. Drug

    Matrix-M

    go.drugbank.com/drugs/DB16369
    Investigational

    Matrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax. This compound is administered alongside vaccines to enhance biological functions: creating robust and long-last...

  9. Drug

    Tisotumab vedotin

    go.drugbank.com/drugs/DB16732
    ApprovedInvestigational

    Tisotumab vedotin is a tissue factor-directed antibody-drug conjugate (ADC) comprised of an anti-tissue factor (TF) human IgG1-kappa antibody conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting … [L38429] Tisotumab vedotin-tftv is marketed under the trade name Tivdak as an intravenous injection. On April 29, 2024, tisotumab vedotin was granted full FDA approval.

  10. Drug

    Moschus berezovskii musk sac resin

    go.drugbank.com/drugs/DB14247
    Investigational

    Moschus berezovskii musk sac resin is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.